FMP
Opiant Pharmaceuticals, Inc.
OPNT
NASDAQ
Inactive Equity
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
20.65 USD
0 (0%)
We are unable to load the chart at this time.
Dr. Roger Crystal M.D.
Healthcare
Biotechnology
NASDAQ
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
0001385508
US6837501039
683750103
233 Wilshirre Boulevard
310 598 5410
US
37
Jun 4, 2007
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001385508
NASDAQ
Biotechnology
Healthcare
683750103
US6837501039
US
20.65
0.83
72.36k
108.8M
-
7.34-27.36
26.31
-
-
-
-
-3.16
-
https://www.opiant.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.